The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
Tao Sun,1,2,* Yanqiao Ren,1,2,* Bo Sun,1,2,* Lei Chen,1,2 Licheng Zhu,1,2 Lijie Zhang,1– 3 Chuansheng Zheng1,2 1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Hubei Pro...
Main Authors: | Sun T, Ren Y, Sun B, Chen L, Zhu L, Zhang L, Zheng C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-03-01
|
Series: | Journal of Hepatocellular Carcinoma |
Subjects: | |
Online Access: | https://www.dovepress.com/the-feasibility-of-tace-combined-with-tkis-plus-pd-1-antibody-for-adva-peer-reviewed-fulltext-article-JHC |
Similar Items
-
Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation
by: Yin L, et al.
Published: (2022-09-01) -
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
by: Jinpeng Li, et al.
Published: (2023-07-01) -
A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
by: Xiaomi Li, et al.
Published: (2023-08-01) -
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
by: Dominik Bettinger, et al.
Published: (2018-08-01) -
Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
by: Ran You, et al.
Published: (2022-08-01)